New transplant strategy aims to stop AML from coming back
NCT ID NCT07572695
First seen May 09, 2026 · Last updated May 13, 2026 · Updated 1 time
Summary
This study looks at a stem cell transplant from a half-matched donor for adults aged 18-65 with acute myeloid leukemia (AML) that has returned or not responded to treatment. After the transplant, patients receive extra medicines and immune cells to help prevent the cancer from coming back. The goal is to see if this approach can improve survival and control the disease better than standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.